Q1 Earnings Estimate for PTN Issued By HC Wainwright

Palatin Technologies (NASDAQ:PTN) – Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Palatin Technologies in a note issued to investors on Friday, November 6th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.32) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Palatin Technologies’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Palatin Technologies’ Q2 2027 earnings at ($0.33) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.49) EPS and FY2027 earnings at ($1.50) EPS.

Separately, Weiss Ratings initiated coverage on Palatin Technologies in a report on Wednesday, November 4th. They set a “sell (e+)” rating for the company. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Palatin Technologies has an average rating of “Hold” and a consensus price target of $12.00.

Palatin Technologies Price Performance

PTN stock opened at $7.23 on Monday. Palatin Technologies has a 52-week low of $4.51 and a 52-week high of $31.00.

About Palatin Technologies

Palatin Technologies is a biopharmaceutical company that develops peptide-based medicines designed to act on specific receptors. Its research has focused primarily on the melanocortin system, which is involved in a range of biological functions and potential therapeutic applications.

The company’s commercial product is Vyleesi (bremelanotide), an injectable prescription medicine approved in the United States to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.